

NeuroPro Technologies













OVERVIEW









   
                HOME


 
   Profile











 




[profile]


[management]


[advisory board]


[opportunities]





    
                Founded in 2001, NeuroPro Technologies is a neuroscience-focused
                company with programs ranging from diagnostics to implantable
                devices and new therapeutics.  NeuroPro was founded by two 
                practicing
                neurosurgeons, a molecular biologist, and an experienced 
                entrepreneur.

    With laboratories  and offices in Northern 
                California, NeuroPro Technologies, Inc. is a privately-held 
                company.


Home |
Overview |
R&D Portfolio | 
Careers | 
Contact Us | 
NeuroPro In the 
News









� 
            Copyright 2006-2011. All rights reserved


            NeuroPro Technologies, Inc.






Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version














NeuroPro Therapeutics, Inc., Patent Owner, BAHAMA, NC























































Patent Buddy

Sign In     |     Join Today





















Free



Premium



Professional



Enterprise








Patent Searching

 

 

 



Technology Searching






Owner and Inventor Searching






Patent Analytics






Owner Analytics






Attorney Analytics






Inventor Analytics






Technology Analytics






Mobile Searching






Tagging






Advanced Patent Analytics

 

 

 



Advanced Owner Analytics






Mobile Portfolio/Analytics






Detailed Attorney Information






Prosecution analytics






Pre-publication Data






Monthly PAIR Information and Watches







						Number of patents in all portfolios
						
100 (maximum)
1000 (maximum)
2000 (maximum)
Unlimited


Follows
							in all categories (Watch)

						10 (maximum)
						
50 (maximum)
500 (maximum)
Unlimited


Maximum number of portfolios
5 (maximum)
10 (maximum)
100 (maximum)
Unlimited


Maximum number of comparisons
1 (maximum)
 
5 (maximum)
 
20 (maximum)
 
Unlimited










FREE

 

$9.95/mo

 

$39.95/mo

 

$99.95/mo



 
 
 
 
 
 



PAIR
									Watch Weekly Update
$2.75/mo/patent
$2.65/mo/patent


PAIR
									Watch Daily Update
$5.75/mo/patent
$5.55/mo/patent


Upgrade Now

 
Upgrade Now

 
Upgrade Now

 
Upgrade Now










Welcome to PatentBuddy 2.0!  Please enjoy the 30+ day free trial of our  level membership.  If you wish to continue with a paid membership, please select a membership plan before the year end expiration date.  Otherwise, all portfolios and followings will be reset to our free membership plan after the expiration date.






Free



Premium



Professional



Enterprise








Patent Searching

 

 

 



Technology Searching






Owner and Inventor Searching






Patent Analytics






Owner Analytics






Attorney Analytics






Inventor Analytics






Technology Analytics






Mobile Searching






Tagging






Advanced Patent Analytics

 

 

 



Advanced Owner Analytics






Mobile Portfolio/Analytics






Detailed Attorney Information






Prosecution analytics






Pre-publication Data






Monthly PAIR Information and Watches







						Number of patents in all portfolios
						
100 (maximum)
1000 (maximum)
2000 (maximum)
Unlimited


Follows
							in all categories (Watch)

						10 (maximum)
						
50 (maximum)
500 (maximum)
Unlimited


Maximum number of portfolios
5 (maximum)
10 (maximum)
100 (maximum)
Unlimited


Maximum number of comparisons
1 (maximum)
 
5 (maximum)
 
20 (maximum)
 
Unlimited










FREE

 

$9.95/mo

 

$39.95/mo

 

$99.95/mo



 
 
 
 
 
 



PAIR
									Watch Weekly Update
$2.75/mo/patent
$2.65/mo/patent


PAIR
									Watch Daily Update
$5.75/mo/patent
$5.55/mo/patent


Upgrade Now

 
Upgrade Now

 
Upgrade Now

 
Upgrade Now









Please Confirm Your Upgraded Plan Purchase By Selecting Upgrade Button

  Yearly (Get 12 months for the price of 11!)  MonthlyUPGRADECANCEL












Free



Premium



Professional



Enterprise








Patent Searching

 

 

 



Technology Searching






Owner and Inventor Searching






Patent Analytics






Owner Analytics






Attorney Analytics






Inventor Analytics






Technology Analytics






Mobile Searching






Tagging






Advanced Patent Analytics

 

 

 



Advanced Owner Analytics






Mobile Portfolio/Analytics






Detailed Attorney Information






Prosecution analytics






Pre-publication Data






Monthly PAIR Information and Watches







						Number of patents in all portfolios
						
100 (maximum)
1000 (maximum)
2000 (maximum)
Unlimited


Follows
							in all categories (Watch)

						10 (maximum)
						
50 (maximum)
500 (maximum)
Unlimited


Maximum number of portfolios
5 (maximum)
10 (maximum)
100 (maximum)
Unlimited


Maximum number of comparisons
1 (maximum)
 
5 (maximum)
 
20 (maximum)
 
Unlimited










FREE

 

$9.95/mo

 

$39.95/mo

 

$99.95/mo



 
 
 
 
 
 



PAIR
									Watch Weekly Update
$2.75/mo/patent
$2.65/mo/patent


PAIR
									Watch Daily Update
$5.75/mo/patent
$5.55/mo/patent


Upgrade Now

 
Upgrade Now

 
Upgrade Now

 
Upgrade Now










Please Confirm Your Upgraded Plan Purchase By Selecting Upgrade Button

  Yearly (Get 12 months for the price of 11!)  MonthlyUPGRADECANCEL

















false



NeuroPro Therapeutics, Inc.
Patent Owner







Follow
Compare
Add to Portfolio


Stats


								
							3 
								
							  US PATENTS IN FORCE


								
							1
								
							 
					 US APPLICATIONS PENDING


Jun 20, 2017
 most recent publication





Details


							
								
							3
							
					 Issued Patents

							
								
							1
							
					 Issued in last 3 years

							
								
							1
							
					 Published in last 3 years


 
								
							21
							
					 Total Citation Count

							
							
								
							Apr 07, 2005
							
					 Earliest Filing

							
								
							1
							
					 Expired/Abandoned/Withdrawn Patents




Patent Activity in the Last 10 Years





Technologies


back





Intl Class
Technology
Matters
Rank in Class





 

 


 C07C ACYCLIC OR CARBOCYCLIC COMPOUNDS 3126 SubclassesTop Owners


 

 


 A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 2258 SubclassesTop Owners


 

 


 C07D HETEROCYCLIC COMPOUNDS 2153 SubclassesTop Owners



Show Top 10
										…







Intl Class
Technology
Matters
Rank in Class









Top Patents (by citation)




Upgrade to the Premium Level to View Top Patents for this Owner.
Learn More







Recent Publications


Publication #
Title
Filing Date
Pub Date
Intl Class


2015/0239,832 ANALOGS AND PRODRUGS OF LOOP DIURETICS, INCLUDING BUMETANIDE, FUROSEMIDE AND PIRETANIDE; COMPOSITIONS AND METHODS OF USESep 03, 13Aug 27, 15[C07D, C07C]





Recent Patents


Patent #
Title
Filing Date
Issue Date
Intl Class


9682928 Bumetanide analogs, compositions and methods of useAug 28, 14Jun 20, 17[C07D, C07C, A61K]8722668 Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disordersApr 07, 05May 13, 14[A61K]8008283 Methods and compositions for the treatment of neuropsychiatric disordersOct 17, 05Aug 30, 11[C07C]




Expired/Abandoned/Withdrawn Patents


Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class


2014/0066,504 ANALOGS AND PRODRUGS OF BUMETANIDE; COMPOSITIONS AND METHODS OF USEABANSep 03, 13Mar 06, 14[C07C]





Top Inventors for This Owner




Upgrade to the Premium Level to View Top Inventors for this Owner.
Learn More








Add Patents to Portfolio


  Existing Portfolios  Create New Portfolio


									Add Portfolio
								

 

User Portfolios

  
								You have not yet added any portfolios.
							

 
							OK
						
 





















We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our  Level for up to -1 comparisons!












We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our  Level for up to -1 portfolios!.


























Discover the top patent resource on the web.
Create a Patent Buddy account today and discover why over 250,000 people currently use Patent Buddy as a patent analytics resource.
Join TodayNo credit card required
Already have an account? Sign In ›







Note
The template below is formatted to ensure compatibility with our system.
							Provide tags with | separated like (tags1|tags2).

Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.

Acceptable Date Format - 'MM/DD/YYYY'.

Acceptable Filing/App Types - 

Continuation/Divisional
Original
Paris Convention
PCT National
With Priority
EP Validation
Provisional Conversion
Reissue
Provisional
Foreign Extension

Acceptable Status - 

Pending
Abandoned
Unfiled
Expired
Granted

Acceptable Matter Types - 

Patent
Utility Model
Supplemental Protection Certificate
Design
Inventor Certificate
Plant
Statutory Invention Reg



Advertisement


  




Advertisement

Email Yourself the App Links



Advertisement






Advertisement





Advertisement





Recipient Email Address 


Send Email





Recipient Email Address 

Send Email



Comment 







Recipient Email Address 

Send Email






Success
E-mail has been sent successfully.




Failure
Some error occured while sending email. Please check e-mail and try again!








We are sorry but your current membership does not allow you access to this feature. Upgrade to our Premium Level to View Top Owners in Class/Subclass!



Learn More












View Full Site

	Copyright 2017 PatentBuddy.
Help | Advertise | Contact | Terms | Privacy | About Usfalse











NeuroPro Therapeutics Inc. | North Carolina Biotech Center

























Jump to navigation







We make connections that create biotech jobs.














NCBiotech Company Directory
A comprehensive listing of North Carolina's life science industry | New search


 









NeuroPro Therapeutics Inc.


NeuroPro Therapeutics is developing a novel, nanoparticle-based imaging technique for the treatment of epilepsy.
 


 
 


Location
9803 Colt DriveBahama, NC 27503Phone (919) 812-0485County DurhamRegion Triangle 






 
 


Company classification


Company type Bioscience Company Year founded 2014Employment in NC 1-19US headquarters North CarolinaGlobal headquarters United States 

Company activities Research and DevelopmentCore capabilities Nanotechnology 

Potential end market(s)
DevicesNervous System






 















Funding
Business Services
Job Services








News & Events
About Us
Biotech in NC


















  



  



  



  



  






 
Become a sponsor | Sponsor login


 
 











Questions about the NCBiotech Company Directory?
library@ncbiotech.org
15 TW Alexander Drive
Post Office Box 13547
Research Triangle Park, NC 27709-3547
Directions






The NCBiotech Library strives to provide accurate and current data on the bioscience community in North Carolina. The NCBiotech Company Directory is copyrighted by the North Carolina Biotechnology Center. When citing information in the Directory, attribute as: "North Carolina Biotechnology Center Company Directory, directory.ncbiotech.org.” To reproduce content from the Directory, contact the NCBiotech Library.







Stay connected

Twitter
Facebook
LinkedIn
YouTube




Privacy
Legal
Accessibility


  











NEUROPRO THERAPEUTICS, INC. - Biotechnology- Hochman  FormDs.com - SEC filings of fundraisings and investments in hedge funds, private equity firms, startups, and growing companies 











 FormDs.com 





 Newest
 Filter
 Local




 









NEUROPRO THERAPEUTICS, INC.

      Industry: Biotechnology
      (See others in industry)

Address:



    9803 Colt Drive  
    Bahama, NC, 27503Phone: 919-812-0485 




Filings



Date
FilingType
Reported Sold
Incremental Cash 
Type
Exemptions
Link to Raw Filing




	2016-12-13


Amended


$215,950


$50,950


Equity Only


06b


SEC link




	2016-08-03


New


$165,000


$165,000


Equity Only


06b


SEC link






Directors and Executives (Current and Past)



Name
Role



 Daryl Hochman 
 Director, Executive 





















 




NEUROPRO THERAPEUTICS, INC. $165,000 Financing | Newest SEC Filings

















Newest Filings











NEUROPRO THERAPEUTICS, INC. $165,000 Financing
NEUROPRO THERAPEUTICS, INC. just submitted form D announcing $165,000 equity financing.  This is a new filing. NEUROPRO THERAPEUTICS, INC. was able to sell $165,000. That is 100% of the round of financing. The total private offering amount was $165,000. The financing was made by 2 investors. Minimal accepted investment was $0. The financing document was filed on 2016-08-03. NEUROPRO THERAPEUTICS, INC. is based in  9803 COLT DRIVE  BAHAMA 27503. The firm's business is Biotechnology. The firm's revenue range is Decline to Disclose. The form was signed by  DARYL HOCHMAN.





SEC FORM D


The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.



UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM DNotice of Exempt Offering of Securities


OMB APPROVAL


OMB Number:
3235-0076

Estimated average burden

hours per response:
4.00






1. Issuer's Identity


CIK (Filer ID Number)
Previous Names

X
None

Entity Type


0001681407




X
Corporation


  
Limited Partnership


  
Limited Liability Company


  
General Partnership


  
Business Trust


  
Other (Specify)





Name of Issuer
NEUROPRO THERAPEUTICS, INC.
Jurisdiction of Incorporation/Organization
NORTH CAROLINA
Year of Incorporation/Organization


  
Over Five Years Ago


X
Within Last Five Years (Specify Year)
2014


  
Yet to Be Formed



2. Principal Place of Business and Contact Information

Name of Issuer
NEUROPRO THERAPEUTICS, INC.

Street Address 1
Street Address 2

9803 COLT DRIVE

City
State/Province/Country
ZIP/PostalCode
Phone Number of Issuer


BAHAMA
NORTH CAROLINA
27503
919-812-0485


3. Related Persons


Last Name
First Name
Middle Name


HOCHMAN
DARYL


Street Address 1
Street Address 2

9803 COLT DRIVE

City
State/Province/Country
ZIP/PostalCode


BAHAMA
NORTH CAROLINA
27503



Relationship:
X
Executive Officer
X
Director
  
Promoter

Clarification of Response (if Necessary):

4. Industry Group



  
Agriculture



Banking & Financial Services





  
Commercial Banking


  
Insurance


  
Investing


  
Investment Banking


  
Pooled Investment Fund







Is the issuer registered as an investment company under the Investment Company Act of 1940? 




  
Yes
  
No



  
Other Banking & Financial Services




  
Business Services



Energy




  
Coal Mining





  
Electric Utilities





  
Energy Conservation





  
Environmental Services





  
Oil & Gas





  
Other Energy






Health Care




X
Biotechnology





  
Health Insurance





  
Hospitals & Physicians





  
Pharmaceuticals





  
Other Health Care



  
Manufacturing



Real Estate




  
Commercial





  
Construction





  
REITS & Finance





  
Residential





  
Other Real Estate





  
Retailing


  
Restaurants



Technology




  
Computers





  
Telecommunications





  
Other Technology




Travel




  
Airlines & Airports





  
Lodging & Conventions





  
Tourism & Travel Services





  
Other Travel



  
Other



5. Issuer Size










Revenue Range
OR
Aggregate Net Asset Value Range


  
No Revenues
  
No Aggregate Net Asset Value


  
$1 - $1,000,000
  
$1 - $5,000,000


  
$1,000,001 - $5,000,000
  
$5,000,001 - $25,000,000


  
$5,000,001 - $25,000,000
  
$25,000,001 - $50,000,000


  
$25,000,001 - $100,000,000
  
$50,000,001 - $100,000,000


  
Over $100,000,000
  
Over $100,000,000


X
Decline to Disclose
  
Decline to Disclose


  
Not Applicable
  
Not Applicable



6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)



  
Rule 504(b)(1) (not (i), (ii) or (iii))


  
Rule 504 (b)(1)(i)


  
Rule 504 (b)(1)(ii)


  
Rule 504 (b)(1)(iii)


  
Rule 505


X
Rule 506(b)


  
Rule 506(c)


  
Securities Act Section 4(a)(5)




  
Investment Company Act Section 3(c)


  
Section 3(c)(1)
  
Section 3(c)(9)  


  
Section 3(c)(2)
  
Section 3(c)(10)


  
Section 3(c)(3)
  
Section 3(c)(11)


  
Section 3(c)(4)
  
Section 3(c)(12)


  
Section 3(c)(5)
  
Section 3(c)(13)


  
Section 3(c)(6)
  
Section 3(c)(14)


  
Section 3(c)(7)



7. Type of Filing


X
New Notice

Date of First Sale
2016-07-28

  
First Sale Yet to Occur


  
Amendment


8. Duration of Offering

Does the Issuer intend this offering to last more than one year?


  
Yes
X
No


9. Type(s) of Securities Offered (select all that apply)









X
Equity
  
Pooled Investment Fund Interests


  
Debt
  
Tenant-in-Common Securities


  
Option, Warrant or Other Right to Acquire Another Security
  
Mineral Property Securities


  
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
  
Other (describe)







10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?


  
Yes
X
No


Clarification of Response (if Necessary):
11. Minimum Investment

Minimum investment accepted from any outside investor

$0

USD

12. Sales Compensation


Recipient

Recipient CRD Number
X
None




(Associated) Broker or Dealer
X
None


(Associated) Broker or Dealer CRD Number
X
None



Street Address 1
Street Address 2


City
State/Province/Country
ZIP/Postal Code



State(s) of Solicitation (select all that apply)Check “All States” or check individual States
  
All States


  
Foreign/non-US



13. Offering and Sales Amounts


Total Offering Amount

$165,000

USD

or
  
Indefinite



Total Amount Sold

$165,000

USD


Total Remaining to be Sold

$0

USD

or
  
Indefinite



Clarification of Response (if Necessary):
14. Investors


  
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.




Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
2


15. Sales Commissions & Finder's Fees Expenses
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.


Sales Commissions

$0

USD

  
Estimate



Finders' Fees

$0

USD

  
Estimate



Clarification of Response (if Necessary):
16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.



$0

USD

  
Estimate


Clarification of Response (if Necessary):
Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
Terms of Submission

In submitting this notice, each issuer named above is:

Notifying the SEC and/or each State in which this notice is filed of the offering of 
                    securities described and undertaking to furnish them, upon written request, in the accordance with applicable
                    law, the information furnished to offerees.*
Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator 
                    or other legally designated officer of the State in which the issuer maintains its principal 
                    place of business and any State in which this notice is filed, as its agents for service of 
                    process, and agreeing that these persons may accept service on its behalf, of any notice, 
                    process or pleading, and further agreeing that such service may be made by registered or 
                    certified mail, in any Federal or state action, administrative proceeding, or arbitration 
                    brought against it in any place subject to the jurisdiction of the United States, if the 
                    action, proceeding or arbitration (a) arises out of any activity in connection with the 
                    offering of securities that is the subject of this notice, and (b) is founded, directly or 
                    indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange 
                    Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the 
                    Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) 
                    the laws of the State in which the issuer maintains its principal place of business or any State 
                    in which this notice is filed.
Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).


Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.


Issuer
Signature
Name of Signer
Title
Date


NEUROPRO THERAPEUTICS, INC.
/s/ Byron B. Kirkland
Byron B. Kirkland
Attorney-in-Fact
2016-08-03


Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
* This undertaking does not affect any limits Section 102(a) of the National Securities Markets
        Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to
        require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes 
        of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot
        routinely require offering materials under this undertaking or otherwise and can require offering materials only to the
        extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.




NEUROPRO THERAPEUTICS, INC. Financing

DateFiling TypeOfferedSoldRemainingMin. investmentInvest. countExemption / Exlusions
2016-12-13Amended Form D$220,000$215,950$4,050$0406b[view]2016-08-03New Form D$165,000$165,0000$0206b[view]
NEUROPRO THERAPEUTICS, INC. List of ExecutivesDARYL HOCHMAN











Last visited: LAZARD GLOBAL THEMATIC EQUITY TRUST, LAZARD JAPAN FOCUS FUND L P, LAZARD JAPAN VELA FUND, PLC, LAZARD RATHMORE FUND, LTD., LBC Credit Partners Parallel III, L.P.

								© 
							
























Home - Therapeutics Inc.
























































About
Partnering / Investors
Careers
Contact
 








Meet your milestonesThe only full-service dermatology CRO that takes products from concept to approvalDoes your product have a reason to be?Our philosophy extends to both our clients and ourselves: be the best we can beMeet with us




You may wonder what makes us different from other CROs...
OVER 90% OF WHAT WE DO IS DERMATOLOGY.
At Therapeutics we nurture your ideas with thoughtfully integrated solutions. We aim to be your preferred partner.



Let us lead your dermatology product development program through the complex maze of non-clinical, clinical and regulatory hurdles to an FDA approval.Get started 
 

Strategy
CRO Services
Technology Assessment
Our Top 10
Press Room
 









© 2016 Therapeutics, Inc.   Legal  |  PRIVACY
858-571-1800
9025 Balboa Ave., Suite 100, San Diego, CA 92123



© 2016 Therapeutics, Inc.
9025 Balboa Ave., Suite 100, San Diego, CA 92123
858-571-1800

Legal  |  PRIVACY


















NEUROPRO THERAPEUTICS, INC. - List of CEOs, founders and company directors

















directorpedia.net - List of CEOs, founders, board members and company directors











NEUROPRO THERAPEUTICS, INC.
List of persons related to the company NEUROPRO THERAPEUTICS, INC.. Find out list of CEOs, founders, board members, and company directors of NEUROPRO THERAPEUTICS, INC..

CIK Number: 0001681407IRS Number: 464637918Company address: 9803 COLT DRIVE  BAHAMA 27503Phone number: 919-812-0485



People related to NEUROPRO THERAPEUTICS, INC.
NamePositionStreetCityCountryHOCHMAN  DARYL9803 COLT DRIVE BAHAMANC




NEUROPRO THERAPEUTICS, INC. on the Web












 









Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft














neuropro - NetFind Content Results










AOL Search
Skip over navigation


















Search the Web




























Web


Web



Content











FDA Approved - XIAFLEX®



Ad
 ·
xiaflex.com



Collagenase Clostridium Histolyticum. See PI, Boxed Warning





Find a Specialist



XIAFLEX® Safety Info




Acquiring XIAFLEX®



Sign Up for Updates





CIC Information - Learn About Side Effects



Ad
 ·
www.cic-hcp.com/​physician_site



Learn About a Once-Daily Treatment Option for Chronic Idiopathic Constipation.




2017's Top 10 Brain Pills - 10 Brain Pills That Work



Ad
 ·
BrainHealthSupplements.org



2017's 10 Best Brain Pills That Work! 100% Money Back Guarantee & Free Shipping





10 Best Brain Supplements



Brain Supplement Reviews



2017 Top Brain Supplement





Peripheral Neuropathy - Peripheral Neuropathy.



Ad
 ·
Reference.com



Peripheral Neuropathy. Search Our Easy-To-Read Articles.



Results From The WOW.Com Content Network

Ginseng shows Parkinson's prevention promise - Yahoo

https://ca.news.yahoo.com/ginseng-shows-parkinsons-prevention...


Human trials for the ginseng supplement NeuroPro could take two years, says Jackalina Van Kampen.


Walid Juffali - WOW.com

www.wow.com/wiki/Walid_Juffali


Walid Juffali; Born: Walid Ahmed Juffali 30 April 1955: Died: ... The CEO is Jamil El Imad, who is also managing director and chief scientist of his NeuroPro company.


Smart Wearables in Healthcare, 2016-2030 - 250 Smart ...

https://finance.yahoo.com/news/smart-wearables-healthcare-2016...


- NeuroPro - NeuroSky - New York State University - Nike - Novartis - NovioSense - Novo A/S - Numera (now Nortek) - Nutrivise - Nuubo - NXP Semiconductor - Omate - Omron


Surgery can cure 18% epilepsy patients, says Swiss researcher

https://uk.news.yahoo.com/surgery-cure-18-epilepsy-patients-says...


Surgery can cure 18% epilepsy patients, says Swiss researcher. Saudi Gazette. 4 December 2013. Reblog. Share. ... Jamil El-Imad, the managing director of NeuroPro, ...


Un tétraplégique retrouve l’usage de son bras et de sa ...

https://fr.news.yahoo.com/tétraplégique-retrouve-l-usage-bras...


C'est une prouesse médicale, un homme tétraplégique depuis un accident de vélo vient de retrouver l'usage de son bras droit et de sa main grâce à une ...


Autism, any new help out there? | Yahoo Answers

https://answers.yahoo.com/question/index?qid=20060730082427AA6pAiQ


I have a 3 yr. oldl Autistic son who also has Sensory intergration, and Adhd. Have your tryed FGF2 (Neuropro) It's a bovine protein which stimulates the ...


Smart Wearables in Healthcare, 2016-2030 - 250 Smart ...

https://sg.finance.yahoo.com/news/smart-wearables-healthcare-2016...


DUBLIN, September 26, 2016 /PRNewswire/ -- Research and Markets has announced the addition of the "Smart Wearables in Healthcare, 2016-2030" report to their offering.










FDA Approved - XIAFLEX®



Ad
 ·
xiaflex.com



Collagenase Clostridium Histolyticum. See PI, Boxed Warning





Find a Specialist



XIAFLEX® Safety Info




Acquiring XIAFLEX®



Sign Up for Updates





CIC Information - Learn About Side Effects



Ad
 ·
www.cic-hcp.com/​physician_site



Learn About a Once-Daily Treatment Option for Chronic Idiopathic Constipation.




2017's Top 10 Brain Pills - 10 Brain Pills That Work



Ad
 ·
BrainHealthSupplements.org



2017's 10 Best Brain Pills That Work! 100% Money Back Guarantee & Free Shipping





10 Best Brain Supplements



Brain Supplement Reviews



2017 Top Brain Supplement





Peripheral Neuropathy - Peripheral Neuropathy.



Ad
 ·
Reference.com



Peripheral Neuropathy. Search Our Easy-To-Read Articles.



Searches related toneuropro



neupro patch side effects


neuropro inc


neupro patch


neupro patch generic



neupro patch for parkinson's


neuro pro monitoring


rotigotine


patch for parkinson's disease






Related Searches



neupro patch side effects


neuropro inc


neupro patch


neupro patch generic


neupro patch for parkinson's


neuro pro monitoring


rotigotine


patch for parkinson's disease




















Search the Web

















© AOL Inc. All Rights Reserved.Privacy
 | Terms of Use
 | Preferences
 | Contact Us
 | Powered by Bing™

Wow.com - Part of the AOL Search Network








